SIRT2 and diffuse large B-cell lymphoma: The resulting inhibitor YC8-02 demonstrated improved Sirt3 inhibition in vitro and enhanced mitochondrial penetration in the Karpas 422 diffuse large B cell lymphoma (DLBCL) cell line compared to JH-T4; however, YC8-02 still inhibited Sirt1 and Sirt2 with IC50 values of 2.8 μM and 62 nM, respectively [194].